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formulation resulted in less erosion from the total brand. In cases where branded 
utilization is not converted to TR formulation prior to launch of generic competition, 
such as risperidone and ﬂuoxetine, or TR launch precedes generic launch by less than 
six months or not at all, such as azythromycin and sertraline, dramatic reduction in 
total sales brand was observed. In the unique case where branded escitalopram was 
introduced prior to the generic launch of citalopram, an effect similar to a branded 
TR launch was observed. CONCLUSIONS: While generic use typically replaces the 
majority of branded equivalents in a short timeframe, branded products with a time-
release formulation may limit uptake rate of the generic version of the total branded 
product.
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PUBLIC HEALTH AND ECONOMIC IMPACT OF 13-VALENT 
PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) IN AN INFLUENZA 
PANDEMIC IN SINGAPORE AND HONG KONG
Rubin J1, McGarry L1, Klugman K2, Strutton D3, Gilmore K1, Hwang S3, Rinaldi F4, 
Weinstein M5
1i3 Innovus, Medford, MA, USA, 2Rollins School of Public Health, Emory University, Atlanta, 
GA, USA, 3Pﬁzer Inc., Collegeville, PA, USA, 4Independent Consultant to Wyeth—Asia 
Paciﬁc, London, UK, 5Harvard School of Public Health, Boston, MA, USA
OBJECTIVES: Historic data suggest that most 1918 inﬂuenza pandemic-related 
deaths were due to pneumococcal disease (PD); preliminary evidence shows a similar 
pattern for the 2009 H1N1 inﬂuenza outbreak. Implementation of 13-valent pneu-
mococcal conjugate vaccine (PCV13) national immunization programs would likely 
lessen the impact of a pandemic in Asia-Paciﬁc populations that currently have low 
pneumococcal vaccination rates; our objective was to quantify this impact in Singa-
pore and Hong Kong. METHODS: We used a decision-analytic model to assess the 
impact of PCV13 infant vaccination on PD incidence and mortality in an inﬂuenza 
pandemic in Singapore and Hong Kong versus no vaccination. The model was esti-
mated from published sources; both direct and indirect (herd) effects against PD were 
included. Effectiveness of PCV13 was extrapolated from observed US 7-valent PCV 
(PCV7) data, using assumptions on serotype prevalence in the pre-PCV7 era, and 
PCV13 protection against the 6 serotypes not in PCV7. Country-speciﬁc data were 
used where available; where unavailable, US data were used. To simulate acceleration 
of PD transmission in a ﬂu pandemic, we calibrated to 1918 estimates of country-
speciﬁc incidence and mortality, adjusting mortality for the advent of antibiotics. PD 
incidence and mortality, and total PD-related health-care costs were evaluated over a 
1-year horizon. Results are reported in local 2008 currency. RESULTS: Preliminary 
results of the model indicate that in a pandemic of 1918 severity, PCV13 vaccination 
would prevent 3,300 cases of hospitalized pneumococcal pneumonia and 320 deaths 
in Singapore, and save SGD1.53 million in health-care costs (net of vaccination). In 
Hong Kong, PCV13 would prevent 8,200 cases of hospitalized pneumonia (all-cause), 
and 2,200 pneumonia deaths, respectively; PCV13 would save HKD250 million in 
medical costs. CONCLUSIONS: In an inﬂuenza pandemic affecting the Asia-Paciﬁc 
region, infant vaccination with PCV13 would likely be highly effective in reducing 
pandemic-related deaths, PD cases and associated costs.
PODIUM SESSION III: HEALTH CARE DECISION-MAKER’S CASE 
STUDIES
CASE1
IMPLEMENTATION OF A NONFORMULARY PRESCRIBING 
MONITORING SYSTEMS REVEALS OPPORTUNITIES FOR COST 
SAVINGS IN AN ACADEMIC MEDICAL CENTER
Helmons PJ, Daniels CE
University of California San Diego Medical Center, San Diego, CA, USA
ORGANIZATION: University of California San Diego Medical Center (UCSDMC) 
is a 548 bed academic medical center with an average daily census of 368 patients 
and 23,000 annual discharges. UCSDMC has a large regional footprint as it is the 
only academic medical center in the region and serves as the regions burn center and 
high risk obstetrics and neonatal care center. In addition, UCSDMC was the regions 
ﬁrst level 1 trauma unit. Consequently, patients are admitted to UCSDMC with a wide 
variety of medications and insurance coverage. From a medication safety standpoint, 
outpatient maintenance medication is generally not substituted in our hospital. In 
addition, patients are discouraged to bring their own medication into the hospital to 
assure the quality of the medications. These patient population and policy character-
istics make formulary management particularly challenging, as this practice results in 
a constant baseline use of nonformulary outpatient maintenance medications in our 
inpatient patient population. PROBLEM OR ISSUE ADDRESSED: Detecting trends 
in nonformulary prescribing is important as increased use of nonformulary medica-
tions could indicate an important clinical need of this medication. On the other hand, 
increased use of nonformulary medications in therapeutic areas with equivalent but 
less expensive formulary medications, leads to increased costs. We hypothesized that 
analyzing trends in nonformulary prescribing leads to detection of irrational and more 
expensive, nonformulary medications and therefore to cost savings. GOALS: To 
address these issues, we developed a nonformulary medication use monitoring system 
designed to improve formulary adherence by 50% and detect irrational nonformulary 
use at an early stage. OUTCOMES ITEMS USED IN THE DECISION: Formulary 
adherence is deﬁned as the number of nonformulary medication doses billed divided 
by the total number of doses billed. As an example of irrational prescribing detected 
by this system, cost savings associated with reversing nonformulary levalbuterol use 
to formulary albuterol are reported. IMPLEMENTATION STRATEGY: Trends in 
nonformulary use are monitored using daily, monthly and semi-annual reports.—
Daily monitoring is done by the clinical pharmacist. A report that speciﬁes the non-
formulary orders per nursing unit is sent to each pharmacist for follow up. The 
pharmacist evaluates the order for appropriateness and contacts the physician if 
substitution to a formulary alternative is possible. The intervention is recorded in the 
pharmacy information system and compliance is monitored by the pharmacoeconom-
ics specialist.—Monthly monitoring is done by the pharmacoeconomics specialist. The 
results of this monthly analysis are discussed with the Pharmacist-in-Chief and with 
the Chair of the P&T Committee.—Semi-annual reporting is done by the pharmaco-
economics specialist. Trends in nonformulary prescribing over a six month period are 
discussed at the P&T meeting. An action plan is approved to address the ﬁndings. 
RESULTS: The ﬁrst semi-annual nonformulary prescribing report showed a non-
formulary use of 0.26% of billed doses. The most frequently prescribed nonformulary 
medications were: levalbuterol (bronchodilating agent), latanoprost (ocular glaucoma 
agent), pentosan (bladder relief agent) and Mg-Al plus (magnesium supplement). Based 
on this initial report and the lack of formulary alternatives, the P&T committee added 
the latter three agents to the formulary. However, from a cost savings standpoint, the 
use of levalbuterol at our institution was discouraged as this agent has no known 
beneﬁts over our formulary agent albuterol. At the time of the report, levalbuterol 
was almost 4 times more expensive than albuterol. Collaboration with respiratory 
therapy and pulmonology was sought to educate prescribers and pharmacists about 
the therapeutic equivalence of albuterol and levalbuterol. After these interventions, 
the second semi-annual report showed an 80% decrease of nonformulary use to 
0.05% of billed doses. Levalbuterol use decreased by 67% from an average of 24 
patients per month in the 6 month period before the intervention to 8 patients after 
the intervention. Levalbuterol expenditure decreased from $7800 to $1421 over the 
same period and continues to drop, corresponding to an annualized cost avoidance 
of $8000. LESSONS LEARNED: This case study shows that in an environment where 
formulary management is challenging, a nonformulary prescribing monitoring system 
is successful in decreasing nonformulary prescribing and identifying areas of improve-
ment. The large decrease in use of levalbuterol is only one of the successes resulting 
from this effort. However, by implementing continuous monitoring of nonformulary 
prescribing we expect to detect and prevent these excesses in the future. We acknowl-
edge that the monetary savings of decreasing levalbuterol use and nonformulary 
prescribing as a whole is marginal. However, other beneﬁts of a formulary that is 
better tailored to the institution’s needs could include better inventory management, 
improved medication safety and less interruptions of therapy. This will be the focus 
of a subsequent study.
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COST-EFFECTIVENESS OF DRUGS
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1Premera Blue Cross, Mountlake Terrace, WA, USA, 2University of Washington, 
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4University of Washington, Department of Bioethics and Humanities, Seattle, WA, USA
ORGANIZATION: Premera Blue Cross PROBLEM OR ISSUE ADDRESSED: Tra-
ditional U.S. payer drug selection processes are based on safety, efﬁcacy and drug cost. 
As premiums continue to rise, many plan sponsors have responded by raising member 
cost shares on biologics and other high cost pharmaceuticals. This creates affordability 
barriers for these drugs, regardless of their clinical value, comparative effectiveness or 
cost-effectiveness. GOALS: Our novel cost-effectiveness driven formulary design seeks 
to offset the negative impact of such policies on clinical outcomes and quality of care 
by assigning the drugs that are the most incrementally cost-effective to the lowest 
formulary tiers. OUTCOMES ITEMS USED IN THE DECISION: Comparative effec-
tiveness and safety (clinical beneﬁts and harms as determined by our existing formu-
lary process) and incremental cost-effectiveness ratios of speciﬁc therapies vs. usual 
care alternatives, based on published cost-effectiveness analyses, manufacturer-sub-
mitted cost-effectiveness models and in some cases, models developed internally by 
plan staff. Cost-effectiveness studies are subjected to a quality review process before 
being presented to the formulary committee. IMPLEMENTATION STRATEGY: 
Premera Blue Cross has created a formulary process that assigns each drug to one of 
four tiers based on a set of ﬂexible cost-effectiveness thresholds. Incremental cost-
effectiveness, assessed as rigorously as possible, provides a scientiﬁc, transparent and 
defensible means of maintaining lower cost shares for the highest value drugs, regard-
less of actual prescription cost. In some cases, a drug may fall in more than one tier, 
based on the patient population and the particular indication for which it is being 
used. This presentation describes Premera’s formulary process, how the thresholds for 
each tier were established and how drugs and therapeutic classes are reviewed by an 
external multidisciplinary expert committee, with speciﬁc therapeutic drug class 
outcome examples. This formulary is being offered as part of a new pharmacy beneﬁt 
product addressing a currently unmet market need. RESULTS: Premera’s new formu-
lary process was developed in 2009. This presentation describes the methods used to 
establish incremental cost-effectiveness thresholds for each formulary tier and the 
constitution of an external multidisciplinary expert committee to assign speciﬁc drugs 
to tiers. The rationale and tier assignments for speciﬁc therapeutic drug classes are 
presented as examples. LESSONS LEARNED: Despite limitations to the current avail-
ability of clinical and economic outcomes from well-designed studies on which to base 
tiering decisions, it is possible to implement a credible process based on incremental 
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cost-effectiveness analysis. Initial responses suggest that manufacturers will accept the 
challenge to improve the quality of available evidence to support future decisions.
CASE3
THE VA TECHNOLOGY ASSESSMENT ADVISORY GROUP:  
INFORMING EVIDENCE-BASED POLICY RECOMMENDATIONS FOR 
ROBOTIC PROSTATECTOMY
Adams E
Veterans Health Administration, Boston, MA, USA
ORGANIZATION: Veterans Health Administration (VHA) Ofﬁce of Patient Care 
Services provides policy and program development and oversight of clinical care 
delivered to 7.8m veterans nationally. PROBLEM OR ISSUE ADDRESSED: Should 
VHA adopt robotic prostatectomy (RP) for use in clinical care? If so, how should it 
be implemented? GOALS: (1) Apply a new health technology assessment (HTA) 
process for evaluating FDA-approved non-IT and non-pharmacologic new and emerg-
ing health care technologies that draws upon a wide range of VHA expertise as well 
as clinical research. (2) Make policy recommendations on the need, purchase, and 
implementation of these technologies in VHA clinical care in a timely fashion. OUT-
COMES ITEMS USED IN THE DECISION: Available clinical efﬁcacy/effectiveness, 
cost-effectiveness and safety data from the literature, regulatory status, utilization and 
cost analysis (UCA). IMPLEMENTATION STRATEGY: The Technology Assessment 
Advisory Group (TAAG) applied input from HTA, a clinical expert panel and a utiliza-
tion and cost analysis to make evidence-based recommendations on the acquisition, 
use and funding of RP in VA. RESULTS: As of 2006 evidence from heterogeneous 
case series demonstrated the safety and feasibility of RP. Its clinical use was limited 
by: high initial investment and operating costs; substantial training requirements; and 
lack of multicenter experience and clinical trial data from which to determine effective-
ness and cost-effectiveness relative to current practices. The impact of RP on the design 
and work processes in the surgical theater was also unclear. Fulﬁlling research and 
education missions and enhancing prestige and proﬁt were the primary motivators to 
its technological diffusion. UCA showed that patient recapture estimates of $13,000/
year would not offset the costs unique to the robotic system, and therefore, would 
not be economically viable. There are insufﬁcient research data and cost beneﬁt to 
justify widespread purchase and implementation of this technology solely for RP. 
Cautious diffusion to centers of excellence with skills and infrastructure to support 
the technology was recommended, as were options to help defray costs such as leasing 
the robotic system, providing training to outsiders and/or providing this option to the 
Dept of Defense. LESSONS LEARNED: The TAAG process proved feasible and effec-
tive in supporting informed and timely policy recommendations for the purchase and 
use of RP in a manner that enhances quality of care in a environment of cost-contain-
ment. After a one-year moratorium, VHA guidance was created to help individual 
facilities make an informed make or buy decision based on demonstration of an 
appropriate infrastructure in place to support training, backup, maintenance, and 
outcome data collection. The guidance included site visit and approval from the VHA 
National Surgery Program with oversight of outcome data collection, which continues 
today.
CASE4
NEW FINDINGS FROM INTEGRATING ADMINISTRATIVE AND 
FINANCIAL DATABASES TO ESTIMATE PRICE OF HOSPITALIZATIONS
Wong H1, Levit K2, Sun YC3
1Agency for Healthcare Research and Quality, Rockville, MD, USA, 2Thomson Reuters, 
Washington, DC, USA, 3Thomson Reuters, Santa Barbara, CA, USA
ORGANIZATION: Agency for Healthcare Research and Quality (funding organiza-
tion), Thomson Reuters PROBLEM OR ISSUE ADDRESSED: Hospital administrative 
data have been used in “cost-effectiveness,” “cost-beneﬁt,” and “burden-of-illness” 
studies because they contain large numbers of cases for speciﬁc conditions and pro-
cedures and because charge information is available. While these data generally 
contain information on how much the facility charged for the hospital stay, they lack 
information on the cost to provide care and the amount reimbursed for care. In the 
past, AHRQ developed a set of hospital-level cost-to-charge ratios to estimate the cost 
of providing care. AHRQ is piloting a project to create price-to-charge ratios that will 
be used in conjunction with charge information collected on hospital discharge records 
to estimate the “price” of inpatient hospital care. The term “price” reﬂects the amount 
that hospitals are paid by insurers and consumers based on payer revenue information 
for each hospital. This is the amount of revenue that hospitals actually receive, net of 
any discounts negotiated with insurers. These ratios have been linked to the Healthcare 
Cost and Utilization Project (HCUP) State Inpatient Databases (SID) for 5 states. The 
HCUP SID ﬁles contain the universe of inpatient discharge abstracts (including infor-
mation on charges) in participating States, translated into a uniform format to facili-
tate multi-State comparisons and analyses. Currently, 40 states participate in HCUP, 
encompassing about 90 percent of all U.S. community hospital discharges. The 
impetus for this project is to make health care information more transparent to con-
sumers. While the addition of price information will help consumers make more 
informed choices about hospitalizations for themselves and their families, this infor-
mation will also be valuable for researchers by providing alternatives to measuring 
resource use that are better suited for their studies. This presentation builds on last 
year’s talk by presenting price results for 5 states. GOALS: The short-term goals of 
this project include: · Estimate prices by payer (Medicare, Medicaid, Private, and 
Self-pay) for common diagnoses in 5 states for 2006 · Assess the credibility of esti-
mated prices (“proof-of-concept”) · Evaluate price differences for major payers, geo-
graphic areas, and common diagnoses. The long term goals of this project include: · 
Extend study to a total of 10 states · Create models to estimate prices for HCUP states 
not included in the pilot · Provide states with information on hospital average prices 
that can be used to populate a Website where consumers can explore pricing for 
common diagnoses · Release prices publicly on AHRQ databases to explore inpatient 
pricing by market area to address research issues such as competition among hospitals, 
pricing differentials between payers, relationship between prices and quality, and 
effects of hospital entry on prices. OUTCOMES ITEMS USED IN THE DECISION: 
HCUP data have been used in “cost-effectiveness,” “cost-beneﬁt,” and “burden-of-
illness” studies because they contain large numbers of cases for speciﬁc conditions and 
procedures and because charge and estimated cost information is available. The addi-
tion of estimated prices will provide researchers an additional tool to more effectively 
conduct their studies. IMPLEMENTATION STRATEGY: AHRQ solicited participa-
tion of HCUP Partner organizations that have access to hospital revenue information 
by payer and are willing to release state-level charge and price information broken 
out by the four broad payer groups and broad diagnostic categories. Initially, AHRQ 
is utilizing information from 5 HCUP SID Partner States in conjunction with hospital-
speciﬁc revenue information to develop prices for hospitalizations. RESULTS: Prices 
have been estimated for 5 states. We show the consistency and reasonableness of 
estimated prices by presenting the average prices of speciﬁc diagnosis by payers, states, 
and metropolitan areas. In addition, average prices by bed-size, teaching status, and 
hospital ownership are examined. One important advantage of using “prices” rather 
than “costs” or “charges” is that prices are speciﬁc to each payer group, reﬂecting the 
sum of contractual and other adjustments. We demonstrate the differences in resource 
use as measured by “charges,” “costs,” and “prices.” An explanation of what these 
concepts will be discussed. LESSONS LEARNED: To date, the lessons learned include: 
1. The number of States that collect ﬁnancial information by major payers for each 
hospital is limited. 10 States have been identiﬁed with most of the detailed information 
required. 2. While States may collect gross and net revenue information by payer, not 
all separate these revenues completely for inpatient and outpatient services and for 
the major payer groups. Estimating methods have been developed to address these 
issues. 3. Deﬁnitions of revenues and the level of detailed data collection vary consider-
ably among States and needs to be reconciled.
PODIUM SESSION III: COMPLIANCE/ADHERENCE STUDIES
CM1
ADHERENCE, DISCONTINUATION, AND SWITCHING OF BIOLOGIC 
THERAPIES IN MEDICAID ENROLLEES WITH RHEUMATOID ARTHRITIS
Li P, Blum MA, Feldt JMV, Hennessy S, Doshi JA
University of Pennsylvania, Philadelphia, PA, USA
OBJECTIVES: Biological therapies are an expensive but important advance in the 
management of RA. The potential therapeutic beneﬁts of biologics demonstrated in 
clinical trials may be undermined by poor adherence and early discontinuation of 
treatment (i.e., non-persistence) in clinical practice. This study examined adherence, 
discontinuation, and switching of Rheumatoid Arthritis (RA) biologics over a one year 
period following initiation of the biologic treatment in Medicaid patients with RA. 
METHODS: The study sample consisted of Medicaid patients with RA in California, 
Florida and New York who had newly initiated etanercept (n = 1359), anakinra (n = 
267), or inﬂiximab (n = 1012) between January 1, 2000 and December 31, 2002. 
Adherence (proportion of days covered (PDC) ≥ 0.80), discontinuation (90-day con-
tinuous gap), and switching (initiation of second biologic within 90 days of discontinu-
ation date of index biologic) were measured during the 12-months post-index biologic 
initiation. Sensitivity analyses were conducted by varying the thresholds to deﬁne these 
measures. Logistic regressions examined the factors associated with RA biologic 
adherence and discontinuation. RESULTS: Anakinra users had the lowest mean PDC 
(0.36) and percent adherent patients (10.5%) followed by etanercept users (mean 
PDC:0.57; % adherent:32%) and inﬂiximab users (mean PDC:0.64; % adher-
ent:43%). All three groups had high discontinuation rates (41% etanercept, 76% 
anakinra, and 41% inﬂiximab). Few patients who discontinued the index biologic 
switched to another biologic (0.2% to 9%). Logistic regressions found that patients 
in Florida had lower odds of being adherent and higher odds of discontinuing their 
index biologic than patients in California. Consistent with descriptive results, 
Anakinra users had lower odds and inﬂiximab users had higher odds of being adherent 
than etanercept users. Anakinra users had higher odds of discontinuation than etan-
ercept users. CONCLUSIONS: This study highlights poor adherence and premature 
discontinuation without concurrent switching of RA biologics that should raise 
concern for clinicians as well as payers.
CM2
EFFECTS OF NONADHERENCE WITH ANGIOTENSIN CONVERTING 
ENZYME INHIBITORS/ANGIOTENSIN RECEPTOR BLOCKERS ON 
HOSPITALIZATION AND MORTALITY AMONG PATIENTS WITH 
DIABETES
Yang Y1, Banahan BF1, Pace PF2
1University of Mississippi, University, MS, USA, 2University of Mississippi, Oxford, MS, USA
OBJECTIVES: The objective was to determine the effect of nonadherence to angio-
tensin converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB) and 
subsequent diabetes-related hospitalization and mortality among patients with diabe-
tes enrolled in a state Medicaid program. METHODS: This is a retrospective cohort 
study of patients with diabetes using Medicaid pharmacy and medical claims data. 
